TORNTPHARM - Torrent Pharmaceuticals Ltd. Share Price

Pharmaceuticals & Biotechnology

₹3833.90+14.85(+0.39%)

Market Closed as of Dec 24, 2025, 15:30 IST

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 30.9% return compared to 11.2% by NIFTY 50.

Profitability: Very strong Profitability. One year profit margin are 17%.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: It is among the top 200 market size companies of india.

Balance Sheet: Strong Balance Sheet.

Cons

Smart Money: Smart money is losing interest in the stock.

Insider Trading: Significant insider selling noticed recently.

Valuation
Market Cap	1.22 LCr
Price/Earnings (Trailing)	60.78
Price/Sales (Trailing)	10.31
EV/EBITDA	32.13
Price/Free Cashflow	60.57
MarketCap/EBT	44.16
Enterprise Value	1.22 LCr

Fundamentals
Revenue (TTM)	11.8 kCr
Rev. Growth (Yr)	8.9%
Earnings (TTM)	2 kCr
Earnings Growth (Yr)	19.9%

Profitability
Operating Margin	24%
EBT Margin	23%
Return on Equity	26.37%
Return on Assets	13.36%
Free Cashflow Yield	1.65%

Price to Sales Ratio

Latest reported: 10.3

Revenue (Last 12 mths)

Latest reported: 11.8 kCr

Net Income (Last 12 mths)

Latest reported: 2 kCr

Growth & Returns
Price Change 1W	0.70%
Price Change 1M	1%
Price Change 6M	8.2%
Price Change 1Y	4.7%
3Y Cumulative Return	30.9%
5Y Cumulative Return	23.1%
7Y Cumulative Return	23.2%
10Y Cumulative Return	16.6%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-540 Cr
Cash Flow from Operations (TTM)	2.58 kCr
Cash Flow from Financing (TTM)	-2.3 kCr
Cash & Equivalents	573 Cr
Free Cash Flow (TTM)	1.97 kCr
Free Cash Flow/Share (TTM)	58.33

Balance Sheet
Total Assets	14.99 kCr
Total Liabilities	7.4 kCr
Shareholder Equity	7.59 kCr
Current Assets	5.62 kCr
Current Liabilities	4.72 kCr
Net PPE	3.46 kCr
Inventory	2.54 kCr
Goodwill	339 Cr

Capital Structure & Leverage
Debt Ratio	0.2
Debt/Equity	0.4
Interest Coverage	10.82
Interest/Cashflow Ops	12.09

Dividend & Shareholder Returns
Dividend/Share (TTM)	32
Dividend Yield	0.89%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 30.9% return compared to 11.2% by NIFTY 50.

Profitability: Very strong Profitability. One year profit margin are 17%.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: It is among the top 200 market size companies of india.

Balance Sheet: Strong Balance Sheet.

Cons

Smart Money: Smart money is losing interest in the stock.

Insider Trading: Significant insider selling noticed recently.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.89%
Dividend/Share (TTM)	32
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	59.15

Financial Health
Current Ratio	1.19
Debt/Equity	0.4

Technical Indicators
RSI (14d)	63.68
RSI (5d)	55.76
RSI (21d)	57.48
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
Grufity Signal	Buy
RSI Signal	Hold
RSI5 Signal	Hold
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Latest News and Updates from Torrent Pharmaceuticals

Updated May 4, 2025

The Bad News

Mint

Despite the recent uptick, the stock has declined 2.19% this year.

Mint

The company's TTM P/E ratio stands at 61.06, significantly above the sector average of 27.35.

Mint

The stock has mixed analyst ratings with a portion indicating sell recommendations.

The Good News

Mint

Torrent Pharmaceuticals is currently trading 1.08% higher at Rs 3,284.75.

Mint

The stock gained 1.65% over the past five days, showing a positive short-term trend.

Mint

Analyst coverage indicates a favorable outlook with 4 strong buy and 9 buy ratings.

Updates from Torrent Pharmaceuticals

Analyst / Investor Meet • 27 Oct 2025

Post Quarterly Financial Result Conference call with investors / analyst

General • 21 Oct 2025

Announcement under regulation 30 of SEBI LODR

Credit Rating • 07 Oct 2025

Credit Rating

Credit Rating • 07 Oct 2025

Credit Rating

General • 04 Oct 2025

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Newspaper Publication • 03 Oct 2025

Newspaper advertisement in respect of special window for re-lodgement of transfer request of physical shares

General • 30 Sept 2025

Disclosure u/r 30 of SEBI(LODR) Regulations, 2015

This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.

Earnings Outlook

Last updated:

Q&A Session

Last updated:

Share Holdings

Understand Torrent Pharmaceuticals ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
TORRENT INVESTMENTS LIMITED (FORMERLY KNOWN AS TORRENT INVESTMENTS PRIVATE LIMITED)	0.6831%
NPS TRUST	0.0209%
HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND	0.0115%
MEHTA FAMILY TRUST 1	0%
MEHTA FAMILY TRUST 2	0%
MEHTA FAMILY TRUST 3	0%
MEHTA FAMILY TRUST 4	0%
ANITA SUDHIR MEHTA	0%
SAPNA SAMIR MEHTA	0%
JINAL SUDHIR MEHTA	0%
VARUN SUDHIR MEHTA	0%
SHAAN MEHTA	0%
AMAN MEHTA	0%
SUDHIR UTTAMLAL MEHTA	0%
SAMIR UTTAMLAL MEHTA	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.07 LCr	55.67 kCr	+6.80%	-8.90%	39.14	7.3	-	-
CIPLA	Cipla	1.28 LCr	28.77 kCr	+5.60%	+2.60%	23.72	4.45	-	-
DRREDDY	Dr. Reddy's Lab	1.07 LCr	34.79 kCr	+2.60%	-1.30%	22.9	3.08	-	-
LUPIN	Lupin	87.72 kCr	23.61 kCr	0.00%	-11.00%	23.69	3.72	-	-
AUROPHARMA	Aurobindo Pharma	63.59 kCr	32.56 kCr	+0.40%	-23.30%	18.77	1.95	-	-

Category	TORNTPHARM	Pharmaceuticals
PE	60.78	35.96
PS	10.31	5.07
Growth	6.8 %	6.9 %

Key Insights

1. TORNTPHARM is among the Top 5 Pharmaceuticals companies by market cap.
2. The company holds a market share of 2.6% in Pharmaceuticals.
3. The company is growing at an average growth rate of other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	7.3%	11,516	10,728	9,620	8,508	8,005	7,939
Other Income	-61.4%	23	58	45	197	57	122
Total Income	7%	11,539	10,786	9,665	8,705	8,062	8,061
Cost of Materials	-8.3%	1,520	1,657	1,480	1,538	1,421	1,377
Purchases of stock-in-trade	29.3%	1,531	1,184	1,089	831	1,005	923
Employee Expense	11%	2,203	1,984	1,678	1,526	1,440	1,429
Finance costs	-28.9%	252	354	333	255	358	451
Depreciation and Amortization	-1.6%	795	808	707	662	658	654
Other expenses	4.7%	2,816	2,690	2,365	2,108	1,933	2,173
Total Expenses	3.8%	8,842	8,522	7,818	6,994	6,536	6,874
Profit Before exceptional items and Tax	19.1%	2,697	2,264	1,847	1,711	1,526	1,187
Exceptional items before tax	-128.7%	-24	88	0	-485	0	0
Total profit before tax	13.7%	2,673	2,352	1,847	1,226	1,526	1,187
Current tax	34.1%	619	462	374	342	327	221
Deferred tax	-39.1%	143	234	228	107	-53	-59
Total tax	9.5%	762	696	602	449	274	162
Total profit (loss) for period	15.4%	1,911	1,656	1,245	777	1,252	1,025
Other comp. income net of taxes	-687.5%	-93	17	-137	12	100	-192
Total Comprehensive Income	8.7%	1,818	1,673	1,108	789	1,352	833
Earnings Per Share, Basic	15.7%	56.47	48.94	36.79	22.965	36.99	30.275
Earnings Per Share, Diluted	15.7%	56.47	48.94	36.79	0	36.99	30.275
Debt equity ratio	-	04	-	-	-	-	-
Debt service coverage ratio	-	0.0387	-	-	-	-	-
Interest service coverage ratio	-	0.1243	-	-	-	-	-

Description	(%) Q/Q	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	7.4%	3,178	2,959	2,809	2,889	2,859	2,745
Other Income	-100%	-37	-18	33	-16	24	31
Total Income	6.8%	3,141	2,941	2,842	2,873	2,883	2,776
Cost of Materials	-1.5%	396	402	370	337	411	410
Purchases of stock-in-trade	-18.8%	338	416	420	382	313	315
Employee Expense	7.9%	605	561	549	543	550	486
Finance costs	0%	56	56	57	64	75	80
Depreciation and Amortization	0%	201	201	199	198	197	203
Other expenses	9.1%	767	703	673	729	711	697
Total Expenses	6.7%	2,403	2,252	2,151	2,212	2,227	2,145
Profit Before exceptional items and Tax	7.1%	738	689	691	661	656	631
Exceptional items before tax	96%	0	-24	0	0	0	0
Total profit before tax	11%	738	665	691	661	656	631
Current tax	9.3%	201	184	153	156	126	142
Deferred tax	33.3%	-11	-17	35	52	73	40
Total tax	13.9%	190	167	188	208	199	182
Total profit (loss) for period	10.1%	548	498	503	453	457	449
Other comp. income net of taxes	-108.6%	-2	36	-70	-25	-34	1
Total Comprehensive Income	2.3%	546	534	433	428	423	450
Earnings Per Share, Basic	10.8%	16.19	14.71	14.88	13.37	13.51	13.27
Earnings Per Share, Diluted	10.8%	16.19	14.71	14.88	13.37	13.51	13.27
Debt equity ratio	-	-	04	-	-	-	-
Debt service coverage ratio	-	-	0.0491	-	-	-	-
Interest service coverage ratio	-	-	0.1366	-	-	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	13.5%	9,682	8,533	7,695	6,742	6,451	6,168
Other Income	-65.6%	32	91	82	204	118	237
Total Income	12.6%	9,714	8,624	7,777	6,946	6,569	6,405
Cost of Materials	-8.1%	1,518	1,652	1,477	1,529	1,421	1,353
Purchases of stock-in-trade	33.6%	732	548	534	397	399	341
Employee Expense	12.8%	1,636	1,451	1,251	1,098	1,097	1,062
Finance costs	-29.8%	213	303	298	236	339	430
Depreciation and Amortization	-0.1%	760	761	672	602	610	607
Other expenses	8.2%	2,230	2,061	1,840	1,636	1,487	1,552
Total Expenses	5.6%	7,080	6,707	6,200	5,480	5,203	5,288
Profit Before exceptional items and Tax	37.4%	2,634	1,917	1,577	1,466	1,366	1,117
Exceptional items before tax	-	-24	0	0	0	0	0
Total profit before tax	36.2%	2,610	1,917	1,577	1,466	1,366	1,117
Current tax	68.2%	541	322	274	253	248	192
Deferred tax	-24.1%	181	238	251	222	-20	-14
Total tax	29%	722	560	525	475	228	178
Total profit (loss) for period	39.2%	1,888	1,357	1,052	991	1,138	939
Other comp. income net of taxes	-240%	-41	31	-78	1	110	-115
Total Comprehensive Income	33.1%	1,847	1,388	974	992	1,248	824
Earnings Per Share, Basic	40.1%	55.79	40.1	31.07	29.295	33.62	27.73
Earnings Per Share, Diluted	40.1%	55.79	40.1	31.07	29.295	33.62	27.73
Debt equity ratio	-	034	-	-	-	-	-
Debt service coverage ratio	-	0.0408	-	-	-	-	-
Interest service coverage ratio	-	0.1443	-	-	-	-	-

Description	(%) Q/Q	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	7.5%	2,616	2,433	2,377	2,434	2,438	2,143
Other Income	-142.9%	-5	15	3	-7	21	76
Total Income	6.7%	2,611	2,448	2,380	2,427	2,459	2,219
Cost of Materials	-2%	394	402	369	337	410	409
Purchases of stock-in-trade	-15.7%	173	205	211	175	141	168
Employee Expense	8.9%	453	416	407	407	406	353
Finance costs	-4.3%	45	47	48	54	64	67
Depreciation and Amortization	-1.6%	187	190	191	190	189	195
Other expenses	5.3%	600	570	539	571	550	536
Total Expenses	3.7%	1,869	1,802	1,729	1,757	1,792	1,689
Profit Before exceptional items and Tax	14.9%	742	646	651	670	667	530
Exceptional items before tax	96%	0	-24	0	0	0	0
Total profit before tax	19.3%	742	622	651	670	667	530
Current tax	23.9%	198	160	125	139	117	82
Deferred tax	38.5%	-7	-12	41	71	81	38
Total tax	29.3%	191	148	166	210	198	120
Total profit (loss) for period	16.3%	551	474	485	460	469	410
Other comp. income net of taxes	-366.7%	-27	-5	-7	-29	0	14
Total Comprehensive Income	11.8%	524	469	478	431	469	424
Earnings Per Share, Basic	17.5%	16.28	14	14.33	13.6	13.86	12.12
Earnings Per Share, Diluted	17.5%	16.28	14	14.33	13.6	13.86	12.12
Debt equity ratio	-	-	034	-	-	-	-
Debt service coverage ratio	-	-	0.0511	-	-	-	-
Interest service coverage ratio	-	-	0.1528	-	-	-	-

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	-50%	573	1,146	835	538	508	343
Current investments	32.1%	112	85	141	234	156	463
Loans, current	33.3%	5	4	3	3	2	3
Total current financial assets	-16%	2,746	3,270	3,028	2,699	2,781	2,659
Inventories	11.9%	2,541	2,271	2,279	2,218	2,230	2,328
Total current assets	-4.4%	5,623	5,879	5,611	5,272	5,314	5,218
Property, plant and equipment	7.4%	3,455	3,217	3,297	3,192	2,772	2,741
Capital work-in-progress	-10.9%	367	412	281	263	688	609
Goodwill	0%	339	339	338	337	338	258
Non-current investments	4.9%	44	42	32	43	43	42
Loans, non-current	0%	3	3	3	2	2	2
Total non-current financial assets	17.9%	80	68	72	100	94	84
Total non-current assets	1.7%	9,367	9,209	9,450	9,457	9,683	7,870
Total assets	-0.6%	14,990	15,088	15,061	14,744	15,012	13,219
Borrowings, non-current	-15.7%	1,192	1,414	1,604	2,110	2,496	2,405
Total non-current financial liabilities	-9.7%	1,352	1,497	1,677	2,170	2,570	2,483
Provisions, non-current	12.4%	501	446	445	408	393	390
Total non-current liabilities	-2%	2,682	2,737	2,779	3,139	3,367	3,178
Borrowings, current	12.2%	1,834	1,634	2,334	2,306	2,801	1,613
Total current financial liabilities	-1.6%	4,077	4,144	4,728	4,362	4,919	3,447
Provisions, current	-6.2%	408	435	400	405	394	381
Current tax liabilities	5.6%	96	91	168	8	31	30
Total current liabilities	-2.7%	4,717	4,847	5,426	4,898	5,447	3,950
Total liabilities	-2.4%	7,399	7,584	8,205	8,037	8,814	7,128
Equity share capital	0%	169	169	169	169	169	169
Total equity	1.2%	7,591	7,504	6,856	6,707	6,198	6,091
Total equity and liabilities	-0.6%	14,990	15,088	15,061	14,744	15,012	13,219

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	15.6%	105	91	105	81	85	66
Current investments	32.1%	112	85	141	234	156	463
Loans, current	0%	4	4	3	3	2	3
Total current financial assets	10.6%	2,522	2,280	1,937	2,064	2,095	2,300
Inventories	9.3%	1,561	1,428	1,566	1,577	1,602	1,653
Total current assets	9.9%	4,349	3,958	3,742	3,919	3,926	4,127
Property, plant and equipment	0%	3,132	3,132	3,205	3,113	2,688	2,648
Capital work-in-progress	48%	365	247	204	235	675	604
Goodwill	0%	324	324	324	324	324	244
Non-current investments	2%	411	403	322	218	205	184
Loans, non-current	0%	3	3	3	2	3	2
Total non-current financial assets	1.7%	431	424	342	238	220	195
Total non-current assets	0.5%	8,493	8,450	8,635	8,704	8,946	7,152
Total assets	3.5%	12,842	12,408	12,377	12,623	12,872	11,407
Borrowings, non-current	-27.8%	1,021	1,414	1,604	1,944	2,332	2,242
Total non-current financial liabilities	-23.5%	1,104	1,442	1,620	1,963	2,360	2,277
Provisions, non-current	17%	338	289	282	260	245	232
Total non-current liabilities	-10.1%	2,270	2,525	2,559	2,784	3,007	2,814
Borrowings, current	35.4%	1,526	1,127	1,729	1,733	2,234	1,050
Total current financial liabilities	31.4%	2,598	1,978	2,697	2,723	3,183	1,916
Provisions, current	-1.4%	207	210	171	172	151	132
Current tax liabilities	0%	73	73	30	0	-	-
Total current liabilities	26.4%	2,980	2,357	2,989	2,974	3,409	2,116
Total liabilities	7.5%	5,250	4,882	5,548	5,758	6,416	4,930
Equity share capital	0%	169	169	169	169	169	169
Total equity	0.9%	7,592	7,526	6,829	6,865	6,456	6,477
Total equity and liabilities	3.5%	12,842	12,408	12,377	12,623	12,872	11,407

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-28.7%	252	353	333	255	-	-
Change in inventories	-426%	-262	-49	256	219	-	-
Depreciation	-1.6%	795	808	707	662	-	-
Unrealised forex losses/gains	72.4%	-15	-57	-49	-36	-	-
Adjustments for interest income	90%	20	11	0	0	-	-
Net Cashflows from Operations	-15.3%	3,188	3,764	2,766	2,224	-	-
Income taxes paid (refund)	21.1%	603	498	398	421	-	-
Net Cashflows From Operating Activities	-20.9%	2,585	3,266	2,368	1,803	-	-
Cashflows used in obtaining control of subsidiaries	-	0	0	1,941	0	-	-
Cash payment for investment in partnership firm or association of persons or LLP	-	10	0	0	0	-	-
Proceeds from sales of PPE	-87.2%	18	134	159	6	-	-
Purchase of property, plant and equipment	41.2%	611	433	574	203	-	-
Interest received	58.3%	20	13	13	7	-	-
Other inflows (outflows) of cash	-102.6%	-2	118	-13	-8	-	-
Net Cashflows From Investing Activities	-220.1%	-540	-168	-2,356	-198	-	-
Proceeds from borrowings	-	0	0	2,237	219	-	-
Repayments of borrowings	-32.4%	926	1,369	972	1,033	-	-
Payments of lease liabilities	13%	27	24	22	0	-	-
Dividends paid	6.7%	1,083	1,015	863	677	-	-
Interest paid	-29.5%	262	371	303	258	-	-
Net Cashflows from Financing Activities	17.3%	-2,298	-2,779	77	-1,781	-	-
Effect of exchange rate on cash eq.	-242.9%	-9	8	21	1	-	-
Net change in cash and cash eq.	-180.7%	-262	327	110	-175	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-29.8%	213	303	298	236	-	-
Change in inventories	-88.9%	5	37	218	115	-	-
Depreciation	-0.1%	760	761	672	602	-	-
Impairment loss / reversal	-	1	0	0	15	-	-
Unrealised forex losses/gains	131.6%	13	-37	73	-13	-	-
Dividend income	-102%	0	50	0	0	-	-
Adjustments for interest income	-100%	1	3	0	3	-	-
Net Cashflows from Operations	-4.8%	3,064	3,218	2,538	2,380	-	-
Income taxes paid (refund)	50.9%	490	325	272	240	-	-
Net Cashflows From Operating Activities	-11%	2,574	2,893	2,266	2,140	-	-
Cashflows used in obtaining control of subsidiaries	-	78	0	1,963	24	-	-
Cash payment for investment in partnership firm or association of persons or LLP	-	10	0	0	0	-	-
Proceeds from sales of PPE	-45.2%	18	32	155	3	-	-
Purchase of property, plant and equipment	29.7%	446	344	571	108	-	-
Dividends received	-102%	0	50	0	0	-	-
Interest received	-100%	1	4	9	4	-	-
Other inflows (outflows) of cash	-101.1%	0	90	43	-35	-	-
Net Cashflows From Investing Activities	-58.6%	-470	-296	-2,327	-160	-	-
Proceeds from borrowings	-200%	0	2	2,193	0	-	-
Repayments of borrowings	-36.3%	788	1,236	972	1,043	-	-
Payments of lease liabilities	100%	9	5	5	17	-	-
Dividends paid	6.7%	1,083	1,015	863	677	-	-
Interest paid	-30.7%	224	323	272	240	-	-
Net Cashflows from Financing Activities	18.3%	-2,104	-2,577	81	-1,977	-	-
Net change in cash and cash eq.	-105.3%	0	20	20	3	-	-

Torrent Pharmaceuticals is a prominent pharmaceuticals company with the stock ticker TORNTPHARM and a significant market capitalization of Rs. 112,871.4 Crores. Founded in 1959 and based in Ahmedabad, India, the company was previously known as Trinity Laboratories before changing its name in 1971.

The company specializes in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. Its operations span across multiple countries, including India, the United States, Brazil, Germany, and other international markets.

Torrent Pharmaceuticals offers a wide range of products across various therapeutic areas such as:

Cardiovascular
Central Nervous System
Gastrointestinal
Women's Healthcare
Dermatology
Diabetology
Pain Management
Gynecology
Oncology
Anti-infective
Vitamins, minerals, and nutrients

Additionally, the company provides contract manufacturing services.

With a trailing twelve-month revenue of Rs. 11,374 Crores, Torrent Pharmaceuticals has demonstrated strong profitability, achieving a profit of Rs. 1,862 Crores over the past year. The company has experienced a revenue growth of 33.9% over the last three years.

Investors benefit from its commitment to returning value, as Torrent Pharmaceuticals distributes dividends with a yield of 1.62% per year. In the previous 12 months, the company returned a dividend of Rs. 54 per share. Torrent Pharmaceuticals is a subsidiary of Torrent Investments Private Limited.

Industry Group:Pharmaceuticals & Biotechnology

Employees:15,718

Website:www.torrentpharma.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

TORNTPHARM - Torrent Pharmaceuticals Ltd. Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

The Bad News

The Good News

Updates from Torrent Pharmaceuticals

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Torrent Pharmaceuticals Ltd. do?

Important Disclosure & Data Context

TORNTPHARM - Torrent Pharmaceuticals Ltd. Share Price

TORNTPHARM

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

TORNTPHARM

Investor Care

Financial Health

Technical Indicators

The Bad News

The Good News

Updates from Torrent Pharmaceuticals

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Torrent Pharmaceuticals Ltd. do?

Important Disclosure & Data Context

TORNTPHARM

TORNTPHARM